Ear specialist Otonomy nets $49m from position of strength
This article was originally published in Scrip
The ear disease-focused biotechnology firm Otonomy raised more than originally planned with its $49m Series D venture capital round, but the San Diego-based company courted investors from a position of strength while it still had money from its recent Series C round in the bank.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.